
Vatilen®
Palbociclib
Therapeutic action
Cyclin-dependent kinase inhibitor.
Indications
HR-positive, HER2-negative advanced or metastatic breast cancer.
Presentation
21 hard capsules of 75 mg, 100 mg. or 125 mg.
Cyclin-dependent kinase inhibitor.
HR-positive, HER2-negative advanced or metastatic breast cancer.